Clinical Trial: Combinations of Pharmacologic Smoking Cessation Treatments


	Home	\|	Search	\|	Browse	\|	Resources	\|	Help	\|	What's New	\|	About

Combinations of Pharmacologic Smoking Cessation Treatments

This study is no longer recruiting patients.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs

Purpose

The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.

Condition	Treatment or Intervention	Phase
Smoking	Drug: Bupropion Drug: Mecamylamine Drug: Nicotine Patch	Phase I

MedlinePlus related topics: Smoking

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Further Study Details:

Study start: November 1998; Study completion: June 2001

Eligibility

Ages Eligible for Study: 20 Years - 40 Years, Genders Eligible for Study: Both

Criteria

Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health

Location Information

California
VA Greater Los Angeles Healthcare System, Los Angeles, California, 90073, United States

Study chairs or principal investigators

Neil Hartman, M.D.

More Information

Study ID Numbers: ADRD-011-98S
Record last reviewed: November 2004
Record first received: July 3, 2001
ClinicalTrials.gov Identifier: NCT00018187
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-16

U.S. National Library of Medicine, Contact NLM Customer Service

National Institutes of Health, Department of Health & Human Services